(PharmaNewsWire.Com, September 28, 2017 ) Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) pipeline Target constitutes close to 13 molecules. Out of which approximately 13 molecules are developed by Companies. The latest report Rho Associated Protein Kinase 2-Pipeline Review, H2 2017, outlays comprehensive information on the Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1)-Rho-Associated Protein Kinase 1 (ROCK1) is a protein serine/threonine kinase. It is a key regulator of actin cytoskeleton and cell polarity. It is involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of DAPK3, GFAP, LIMK1, LIMK2, MYL9/MLC2, PFN1 and PPP1R12A. It phosphorylates JIP3 and regulates the recruitment of JNK to JIP3 upon UVB-induced stress. It acts as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. It acts as a negative regulator of VEGF-induced angiogenic endothelial cell activation. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 8 and 2 respectively. Report covers products from therapy areas Cardiovascular, Immunology, Ophthalmology, Central Nervous System, Musculoskeletal Disorders, Respiratory, Dermatology, Gastrointestinal, Metabolic Disorders and Oncology which include indications Glaucoma, Fibrosis, Graft Versus Host Disease (GVHD), Rheumatoid Arthritis, Acute Spinal Cord Injury, Alzheimer's Disease, Autoimmune Disorders, Cerebrovascular Disease, Chronic Obstructive Pulmonary Disease (COPD), Contact Dermatitis, Huntington Disease, Hypersensitivity, Hypertension, Idiopathic Pulmonary Fibrosis, Inflammation, Inflammatory Bowel Disease, Multiple Sclerosis, Plaque Psoriasis (Psoriasis Vulgaris), Pulmonary Arterial Hypertension, Solid Tumor and Traumatic Spinal Cord Injury.
Furthermore, this report also reviews key players involved in Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
List of Tables Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Indications, H2 2017 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Pipeline by Astex Pharmaceuticals Inc, H2 2017 Pipeline by BioAxone BioSciences Inc, H2 2017 Pipeline by HitGen LTD, H2 2017 Pipeline by Kadmon Corp LLC, H2 2017 Pipeline by Pfizer Inc, H2 2017 Pipeline by Redx Pharma Plc, H2 2017 Pipeline by Vertex Pharmaceuticals Inc, H2 2017 Dormant Projects, H2 2017 Discontinued Products, H2 2017
List of Figures Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Top 10 Indications, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017 Number of Products by Molecule Types, H2 2017 Number of Products by Stage and Molecule Types, H2 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
